EUVIMEDEUVIMED entdecken
Open Access

Piplartine attenuates aminoglycoside-induced TRPV1 activity and protects from hearing loss in mice

Marisa Zallocchi, Sarath Vijayakumar, Jonathan Fleegel, Lyudmila Batalkina, Katyarina E Brunette, Dhaval Shukal, Zhiyong Chen, Olivier Devuyst, Huizhan Liu, David Z Z He, Ali Sajid Imami, Abdul-Rizaq Ali Hamoud und 4 weitere

Science Translational Medicine · 2024

DOI: 10.1126/scitranslmed.adn2140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Marisa Zallocchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Creighton University School of Medicine, Omaha, NE 68178, USA. Hauptthemen laut MEDLINE: Piperidones, Hearing Loss, TRPV Cation Channels, Aminoglycosides. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIDCD NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hearing loss is a major health concern in our society, affecting more than 400 million people worldwide. Among the causes, aminoglycoside therapy can result in permanent hearing loss in 40% to 60% of patients receiving treatment, and despite these high numbers, no drug for preventing or treating this type of hearing loss has yet been approved by the US Food and Drug Administration. We have previously conducted high-throughput screenings of bioactive compounds, using zebrafish as our discovery platform, and identified piplartine as a potential therapeutic molecule. In the present study, we expanded this work and characterized piplartine’s physicochemical and therapeutic properties. We showed that piplartine had a wide therapeutic window and neither induced nephrotoxicity in vivo in zebrafish nor interfered with aminoglycoside antibacterial activity. In addition, a fluorescence-based assay demonstrated that piplartine did not inhibit cytochrome C activity in microsomes. Coadministration of piplartine protected from kanamycin-induced hair cell loss in zebrafish and protected hearing function, outer hair cells, and presynaptic ribbons in a mouse model of kanamycin ototoxicity. Last, we investigated piplartine’s mechanism of action by phospho-omics, immunoblotting, immunohistochemistry, and molecular dynamics experiments. We found an up-regulation of AKT1 signaling in the cochleas of mice cotreated with piplartine. Piplartine treatment normalized kanamycin-induced up-regulation of TRPV1 expression and modulated the gating properties of this receptor. Because aminoglycoside entrance to the inner ear is, in part, mediated by TRPV1, these results suggested that by regulating TRPV1 expression, piplartine blocked aminoglycoside’s entrance, thereby preventing the long-term deleterious effects of aminoglycoside accumulation in the inner ear compartment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidonesHearing LossTRPV Cation ChannelsAminoglycosidesMaleFemaleAnimalsMiceZebrafishAnimals, Genetically ModifiedMolecular StructureZebrafish ProteinsSignal TransductionPhosphorylationModels, MolecularProtein Structure, Tertiary

Substanzen

piperlonguminePiperidonesTRPV1 protein, mouseTRPV1 protein, zebrafishTRPV Cation ChannelsZebrafish ProteinsAminoglycosides

Autor:innen und Institutionen

  • Creighton University School of Medicine, Omaha, NE 68178, USA.
  • Institute of Physiology, University of Zürich, Zürich CH-8057, Switzerland.
  • Department of Neurosciences, University of Toledo, Toledo, OH 43614, USA.
  • Neurosciences Institute, ProMedica, Toledo, OH 43614, USA.
  • University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Ting Therapeutics LLC, La Jolla, CA 92037, USA.

Förderung

  • NIGMS NIH HHS
  • NIDCD NIH HHS
  • NCI NIH HHS

Zitieren

APA

Zallocchi, M., Vijayakumar, S., Fleegel, J., Batalkina, L., Brunette, K. E., Shukal, D., Chen, Z., Devuyst, O., Liu, H., He, D. Z. Z., Imami, A. S., Hamoud, A. A., McCullumsmith, R., Conda-Sheridan, M., De Campos, L. J., & Zuo, J. (2024). Piplartine attenuates aminoglycoside-induced TRPV1 activity and protects from hearing loss in mice. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adn2140

Vancouver

Zallocchi M, Vijayakumar S, Fleegel J, Batalkina L, Brunette KE, Shukal D, et al. Piplartine attenuates aminoglycoside-induced TRPV1 activity and protects from hearing loss in mice. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adn2140

BibTeX
@article{Zallocchi2024,
  author = {Zallocchi, Marisa and Vijayakumar, Sarath and Fleegel, Jonathan and Batalkina, Lyudmila and Brunette, Katyarina E and Shukal, Dhaval and Chen, Zhiyong and Devuyst, Olivier and Liu, Huizhan and He, David Z Z and Imami, Ali Sajid and Hamoud, Abdul-Rizaq Ali and McCullumsmith, Robert and Conda-Sheridan, Martin and De Campos, Luana Janaína and Zuo, Jian},
  title = {Piplartine attenuates aminoglycoside-induced TRPV1 activity and protects from hearing loss in mice},
  journal = {Science Translational Medicine},
  year = {2024},
  doi = {10.1126/scitranslmed.adn2140}
}
Kostenlos starten →